1
项与 [89Zr]Zr-DFO-emapalumab 相关的临床试验IFN-y PET Imaging: Bench to Bedside
The goal of this clinical trial is to investigate the use of [89Zr]Zr-DFO-emapalumab as an IFN-γ PET imaging agent to detect lesions and response to therapy among treatment-naïve non-small cell lung cancer (NSCLC) patients. PET scans following the imaging agent will be completed prior to and about 30 days after starting immunotherapy.
100 项与 [89Zr]Zr-DFO-emapalumab 相关的临床结果
100 项与 [89Zr]Zr-DFO-emapalumab 相关的转化医学
100 项与 [89Zr]Zr-DFO-emapalumab 相关的专利(医药)
100 项与 [89Zr]Zr-DFO-emapalumab 相关的药物交易